Ataxia
Conditions
Brief summary
The purpose of this post-marketing surveillance study is to collect and assess information retrospectively on safety and effectiveness of fondaparinux injection in patients with venous thromboembolism (VTE) whose body weight is 100 kilograms (kg) or more, or to whom fondaparinux was injected 10 mg/day. (Arixtra is a trademark of the GlaxoSmithKline group of companies.)
Interventions
For patients whose body weight is 100 kg or more, fondaparinux is injected 10 mg subcutaneously once daily for treatment of acute pulmonary thromboembolism or acute deep venous thrombosis.
Sponsors
GlaxoSmithKline
Study design
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Patients with acute pulmonary thromboembolism or acute deep venous thrombosis * Fondaparinux injection must be prescribed for the first time
Exclusion criteria
* Not applicable
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Presence or absence of reoccurrence of VTE | 3 months |
| Number of patients with adverse drug reaction | 3 months |
| Number of patients with any serious adverse event | 3 months |
| Number of patients with any hemorrhagic adverse event | 3 months |
Outcome results
None listed